Related Experiment Video
Updated: Mar 3, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
Published on: December 3, 2020
Effect of Liver Disease on Hepatic Transporter Expression and Function
Nilay Thakkar1, Jason R Slizgi1, Kim L R Brouwer1
1Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599.
Abstract:
Liver disease can alter the disposition of xenobiotics and endogenous substances. Regulatory agencies such as the Food and Drug Administration and the European Medicines Evaluation Agency recommend, if possible, studying the effect of liver disease on drugs under development to guide specific dose recommendations in these patients. Although extensive research has been conducted to characterize the effect of liver disease on drug-metabolizing enzymes, emerging data have implicated that the expression and function of hepatobiliary transport proteins also are altered in liver disease. This review summarizes recent developments in the field, which may have implications for understanding altered disposition, safety, and efficacy of new and existing drugs. A brief review of liver physiology and hepatic transporter localization/function is provided. Then, the expression and function of hepatic transporters in cholestasis, hepatitis C infection, hepatocellular carcinoma, human immunodeficiency virus infection, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, and primary biliary cirrhosis are reviewed. In the absence of clinical data, nonclinical information in animal models is presented. This review aims to advance the understanding of altered expression and function of hepatic transporters in liver disease and the implications of such changes on drug disposition.
Insights
Liver disease impacts how the body processes drugs by altering hepatic transporter function. This review explores these changes to improve drug safety and efficacy in patients with liver conditions.
Area of Science:
- Pharmacology
- Hepatology
- Drug Metabolism
Background:
- Liver disease significantly affects xenobiotic and endogenous substance disposition.
- Regulatory agencies recommend evaluating drug effects in liver disease patients.
- While drug-metabolizing enzymes are well-studied, hepatic transporter alterations in liver disease are increasingly recognized.
Purpose of the Study:
- To review recent advancements in understanding hepatic transporter expression and function in liver disease.
- To highlight the implications of these changes on drug disposition, safety, and efficacy.
- To provide a foundation for future research and clinical practice.
Main Methods:
- Review of existing literature on hepatic transporter function in various liver diseases.
- Inclusion of data on drug-metabolizing enzymes and transporter proteins.
- Presentation of nonclinical data from animal models where clinical data is lacking.
Main Results:
- Liver disease alters both the expression and function of key hepatic transporters.
- Specific liver conditions like cholestasis, hepatitis C, and hepatocellular carcinoma show distinct transporter changes.
- Altered transporters can lead to significant changes in how drugs are absorbed, distributed, metabolized, and excreted.
Conclusions:
- Understanding hepatic transporter alterations is crucial for managing drug therapy in liver disease.
- Changes in transporter function necessitate careful dose adjustments for many medications.
- This review provides critical insights for drug development and patient care in hepatology.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Hepatic Drug Clearance: Role of Transporters
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...

